Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

6(75.0%)

Phase 1

1(12.5%)

Phase 4

1(12.5%)

8Total

N/A(6)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02526004Not ApplicableCompleted

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Role: collaborator

NCT04489810Not ApplicableCompleted

Digestion of Gluten in the Presence of Enzymes

Role: collaborator

NCT04602468Phase 4Active Not Recruiting

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

Role: collaborator

NCT03362554Not ApplicableActive Not Recruiting

Identification of New Biomarkers of Insulin Resistance

Role: collaborator

NCT05253547Not ApplicableCompleted

Dietary Intervention Study on Food Based Dietary Guidelines for Sustainable and Healthy Lifestyles

Role: collaborator

NCT05986045Not Yet Recruiting

ENHANCE- Establishing Natural History in an Advanced New CF Care Era

Role: collaborator

NCT04489836Not ApplicableCompleted

GlutDigest - Pilot Study

Role: collaborator

NCT03416595Not ApplicableUnknown

A Study on Efficacy of Feeding N1115 Probiotic Supplement to Young Children

Role: collaborator

NCT01896154Phase 1Completed

Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity

Role: collaborator

All 9 trials loaded